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Background: The use of drug eluting stents (DES) declined in 2006 after studies suggested an increased risk of late stent thrombosis compared 
to bare metal stents (BMS). It is unknown how providers weighed the clinical and demographic characteristics of patients when deciding who should 
continue receiving DES. We evaluated trends in a cohort of Medicare beneficiaries older than 65 years treated with DES or BMS for myocardial 
infarction (MI).
Methods: Analysis of Medicare Provider Analysis and Review files from 2004 and 2007; we identified DES or BMS procedures among patients with 
MI by discharge diagnosis and procedure codes. Comorbidities were assigned using a modification of the Healthcare Cost and Utilization Project’s 
comorbidity software. We developed a linear probability model incorporating patient age, gender, socioeconomic status, clinical comorbidies, 
hospital fixed effects, and interaction terms indicating year of revascularization.
Results: The cohort included 118,939 MI episodes treated with DES or BMS (64,630 from 2004 and 54,309 in 2007). DES comprised 72.5% of 
procedures in 2004 and 54.6% in 2007. In 2007, female patients and diabetic patients were more likely to receive DES. Providers were less likely to 
choose DES if a patient was aged 75 or older, being treated for ST-elevation MI, or diagnosed with congestive heart failure, valvular disease, chronic 
lung disease, thrombocytopenia, cancer, or anemia. Compared with 2004 patients, 2007 patients were less likely to receive DES if they were age 80 
or older, female, being treated for ST-elevation MI, had valvular disease, thrombocytopenia, cancer, or anemia. DES use among high income patients 
declined more quickly than among low income patients as DES rates fell. No factors were associated with increased DES use in 2007 compared to 
2004. Thirty-day mortality rates for patients receiving DES or BMS for MI did not change (6.18% in 2004 vs 6.17% in 2007, p=0.93).
Conclusions: Patients receiving DES in 2007 were clinically and demographically distinct from those treated in 2004; in general they were younger 
and had fewer comorbidities. Studies of the long term outcomes of DES should account for changing characteristics of recipients.
